Family Legacy Financial Solutions LLC Takes $5.22 Million Position in Danaher Corporation $DHR

Key Points

• Family Legacy Financial Solutions LLC has invested approximately $5.22 million in Danaher Corporation, acquiring 26,410 shares, which represents about 4.4% of their investment portfolio.
• Several hedge funds have recently increased their stakes in Danaher, with notable increases from GAMMA Investing LLC and Invesco Ltd., highlighting strong institutional interest in the company.
• Analysts have mixed opinions on Danaher, with target prices ranging from $225 to $246.35, indicating a generally positive outlook as evident by a majority "Buy" ratings from investment analysts.

Family Legacy Financial Solutions LLC bought a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 26,410 shares of the conglomerate's stock, valued at approximately $5,217,000. Danaher comprises 4.4% of Family Legacy Financial Solutions LLC's holdings, making the stock its 8th largest holding.

Several other hedge funds have also recently added to or reduced their stakes in DHR. NorthCrest Asset Manangement LLC increased its position in Danaher by 54.7% in the 2nd quarter. NorthCrest Asset Manangement LLC now owns 1,978 shares of the conglomerate's stock worth $402,000 after purchasing an additional 699 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Danaher by 1.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 210,828 shares of the conglomerate's stock valued at $42,840,000 after acquiring an additional 3,659 shares during the last quarter. Tompkins Financial Corp increased its holdings in Danaher by 0.9% during the 2nd quarter. Tompkins Financial Corp now owns 35,741 shares of the conglomerate's stock valued at $7,060,000 after purchasing an additional 335 shares during the period. Baader Bank Aktiengesellschaft lifted its position in shares of Danaher by 22.1% during the 2nd quarter. Baader Bank Aktiengesellschaft now owns 9,606 shares of the conglomerate's stock valued at $1,740,000 after buying an additional 1,741 shares in the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in Danaher by 3.9% in the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 85,472 shares of the conglomerate's stock worth $16,884,000 after acquiring an additional 3,195 shares in the last quarter. Institutional investors own 79.05% of the company's stock.

Danaher Trading Down 1.0%

Shares of Danaher stock traded down $1.96 on Friday, reaching $193.31. The company had a trading volume of 5,932,115 shares, compared to its average volume of 3,243,103. The firm's 50-day moving average price is $200.17 and its two-hundred day moving average price is $198.30. The firm has a market cap of $138.42 billion, a price-to-earnings ratio of 41.13, a P/E/G ratio of 2.70 and a beta of 0.75. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.90. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. Danaher's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period last year, the firm posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio (DPR) is presently 27.23%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Guggenheim reiterated a "buy" rating and issued a $250.00 target price on shares of Danaher in a research report on Wednesday, July 23rd. Evercore ISI reduced their price objective on Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Royal Bank Of Canada set a $241.00 price objective on Danaher in a research note on Tuesday, September 2nd. UBS Group lowered their price objective on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $246.35.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 11.10% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.